Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs United States Natural Gas Fund — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.9 (market cap $977.37M), while United States Natural Gas Fund trades at $11.15 (market cap $503.45M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and United States Natural Gas Fund for 23 Days on average.
| MRVI | UNG | |
|---|---|---|
Market Cap | $977.37M | $503.45M |
Volume | 2,742,564 | 39,591,120 |
Sector | Health | Commodities - Energy |
52-Week High | $9.00 | $16.90 |
52-Week Low | $2.83 | $9.63 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
UNG trades at $11.17, down 2.1% today, amid a bullish technical signal from moving averages but neutral oscillators. The company reported a net income of $65.15 million in 2024 with no revenue, driven by non-operating gains, while cash flow was negative $251.70 million due to financing outflows. Recent news highlights natural gas price volatility from record U.S. production and geopolitical tensions.
Outlook remains cautious due to zero operational revenue and negative cash flow, offset by strong equity of $743.84 million and minimal debt. Risks include reliance on non-recurring income and energy market swings. Analysts lack consensus ratings, but institutional holdings suggest stability despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
